Suppr超能文献

氢化可的松剂量对肾上腺皮质功能不全患者的疼痛、抑郁症状及健康感知的影响:一项随机对照试验

Hydrocortisone Dose Influences Pain, Depressive Symptoms and Perceived Health in Adrenal Insufficiency: A Randomized Controlled Trial.

作者信息

Werumeus Buning Jorien, Brummelman Pauline, Koerts Janneke, Dullaart Robin P F, van den Berg Gerrit, van der Klauw Melanie M, Sluiter Wim J, Tucha Oliver, Wolffenbuttel Bruce H R, van Beek André P

机构信息

Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

出版信息

Neuroendocrinology. 2016;103(6):771-8. doi: 10.1159/000442985. Epub 2015 Dec 9.

Abstract

BACKGROUND

There is a major lack of randomized controlled trials (RCTs) evaluating the effects of hydrocortisone (HC) substitution therapy in patients with secondary adrenal insufficiency. Therefore, we evaluated the effects of two different replacement doses of HC on health-related quality of life (HRQoL) in a RCT.

METHODS

This RCT with a double-blind cross-over design was performed at the University Medical Center Groningen. Forty-seven patients (29 men, age 51 ± 14 years, range 19-73 years) with secondary adrenal insufficiency participated. Patients received both a lower and a higher dose of HC (0.2-0.3 and 0.4-0.6 mg/kg body weight/day) for 10 weeks in random order. HRQoL was assessed with a daily mood and symptom checklist (Patient Health Questionnaire-15 [PHQ-15], Generalized Anxiety Disorder-7 [GAD-7], Patient Health Questionnaire-9 [PHQ-9]) and with questionnaires assessing general well-being (RAND 36-Item Health Survey [RAND-36]), mood (Hospital Anxiety and Depression Scale [HADS]) and fatigue (Multidimensional Fatigue Inventory-20 [MFI-20]). ClinicalTrials.gov identifier: NCT01546922.

RESULTS

Patients receiving the higher dose of HC reported significantly fewer symptoms of depression (p = 0.016 and p = 0.045 for HADS and PHQ-9, respectively), less general and mental fatigue (p = 0.004 and p = 0.003, respectively, both MFI-20), increased motivation (p = 0.021, MFI-20), better physical functioning (p = 0.041), better general health (p = 0.013) and more vitality (p = 0.025) (all RAND-36). In addition, while on the higher dose, fewer somatic symptoms (p = 0.022) and less pain (p < 0.001) (both PHQ-15) were experienced.

CONCLUSIONS

On the higher dose of HC, patients reported a better HRQoL on various domains as compared to the lower dose of HC. The fact that a higher dose of HC may improve patient well-being should be taken into consideration when individualizing the HC substitution dose.

摘要

背景

目前严重缺乏评估氢化可的松(HC)替代疗法对继发性肾上腺功能不全患者疗效的随机对照试验(RCT)。因此,我们在一项RCT中评估了两种不同剂量的HC替代疗法对健康相关生活质量(HRQoL)的影响。

方法

这项采用双盲交叉设计的RCT在格罗宁根大学医学中心进行。47例继发性肾上腺功能不全患者(29例男性,年龄51±14岁,范围19 - 73岁)参与研究。患者随机接受低剂量和高剂量的HC(0.2 - 0.3和0.4 - 0.6mg/kg体重/天)治疗10周。通过每日情绪和症状清单(患者健康问卷 - 15[PHQ - 15]、广泛性焦虑障碍量表 - 7[GAD - 7]、患者健康问卷 - 9[PHQ - 9])以及评估总体幸福感(兰德36项健康调查[RAND - 36])、情绪(医院焦虑抑郁量表[HADS])和疲劳(多维疲劳量表 - 20[MFI - 20])的问卷来评估HRQoL。ClinicalTrials.gov标识符:NCT01546922。

结果

接受高剂量HC治疗的患者报告的抑郁症状显著减少(HADS和PHQ - 9分别为p = 0.016和p = 0.045),总体和精神疲劳减轻(MFI - 20分别为p = 0.004和p = 0.003),动力增强(p = 0.021,MFI - 20),身体功能改善(p = 0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验